Galena Biopharma (GALE) Shares are Down -3.29%

Galena Biopharma (GALE) : During the past 4 weeks, traders have been relatively bearish on Galena Biopharma (GALE), hence the stock is down -12.67% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -3.45% relative to the S&P 500. The 4-week change in the price of the stock is -13.14% and the stock has fallen -3.29% in the past 1 week.

The stock has recorded a 20-day Moving Average of 3.1% and the 50-Day Moving Average is 13.89%.The 200 Day SMA reached 65.45%


Galena Biopharma (NASDAQ:GALE): After opening at $0.33, the stock dipped to an intraday low of $0.323 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $0.3503 and the buying power remained strong till the end. The stock closed at $0.3503 for the day, a gain of 6.64% for the day session. The total traded volume was 1,939,629. The stocks close on the previous trading day was $0.3503.

Galena Biopharma, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapeutics. Its development portfolio ranges from mid- to late-stage clinical assets, including immunotherapy program led by its lead product NeuVax (nelipepimut-S), which is in Phase III clinical trial and is a targeted cancer immunotherapy. NeuVax is the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein, a target for therapeutic intervention in breast and gastric carcinomas. GALE-301 is an immunogenic peptide and can stimulate cytotoxic T lymphocytes to recognize and destroy Folate Binding Protein-expressing cancer cells. GALE-401 is a controlled release formulation of anagrelide. Its commercial drug, Abstral (fentanyl) Sublingual Tablets is a treatment option for inadequately controlled breakthrough cancer pain.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.